Clinical Trial Update: Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants [Phase 3]

View source ↗

Summary

Phase 3 efficacy and safety study of fosmetpantotenate (RE-024) in Pantothenate Kinase-Associated Neurodegeneration (PKAN) was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pantothenate Kinase-associated Neurodegeneration

Drugs mentioned

• fosmetpantotenate (RE-024) (fosmetpantotenate)

Snippet

Sponsor: Travere Therapeutics, Inc. | Conditions: Pantothenate Kinase-Associated Neurodegeneration | Phase 3 | Status: TERMINATED | Results posted: 2020-12-29